|Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free!
AIM-listed bioscience data analytics firm IXICO (LON:IXI) has seen its shares climb by 2.19% to 70p (as of 15:15 GMT) as it posted its first profitable year since joining AIM. Revenues for the 12 months ended 30th September were up by 40% and gross margins were 660 basis points better than during the previous year.
CEO Giulio Cerroni commented: “2019 has been a pivotal year in strengthening IXICO as a trusted technology partner in clinical development. Revenue of £7.6 million built on the growth in 2018, resulting in a 3-year CAGR of 35%. We also achieved our first full year of profitability since admission to AIM. Our strengthened leadership team has allowed us to scale operations and enhanced our strategic planning. With a healthy order book of £15.9 million, new contracts signed since the year end, and a new US-based Chief Business Officer we continue to execute our ambitious growth plans with the aim of delivering another record year“.
The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.
Book your FREE tickets today using code: MIBLOG